$0
Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight Series on Novartis, BMS, and Gilead (Kite)
Since the first US CAR-T approval in 2017, the cell therapy field has rapidly evolved with 5 additional CAR-Ts receiving FDA approval. Nevertheless, challenges surrounding TATs, cost, and patient access still remain. As such, companies are developing innovative strategies to overcome the challenges that the field is currently facing. In the upcoming six-part series, the Celltelligence team will analyze different innovative strategies which the cell therapy leaders (Novartis, BMS, and Gilead) are utilizing to remain competitive in this dynamic space. At the end of the series, Celltelligence will present a semi-qualitative analysis comparing the innovative strategies from Novartis, BMS, and Gilead (Kite).